

# Meredith M Regan, Scd

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3558269/meredith-m-regan-scd-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198  
papers

16,812  
citations

62  
h-index

128  
g-index

207  
ext. papers

19,725  
ext. citations

7.3  
avg, IF

5.87  
L-index

#	Paper	IF	Citations
198	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5794-9	2.2	1390
197	Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 678-83	15.1	816
196	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 297-305	21.7	775
195	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. <i>Cell</i> , <b>2009</b> , 138, 245-56	56.2	691
194	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 133-41 <sup>2.2</sup>	2.2	624
193	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 141-8	21.7	598
192	The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. <i>Nature Genetics</i> , <b>2009</b> , 41, 882-4	36.3	550
191	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 107-18	59.2	500
190	Adjuvant ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 436-46	59.2	462
189	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 766-76	59.2	387
188	Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3846-52	2.2	340
187	Association of cystic fibrosis with abnormalities in fatty acid metabolism. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 560-9	59.2	318
186	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8½ years median follow-up. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1101-8	21.7	298
185	8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 9742-6 <sup>11.5</sup>	11.5	295
184	CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 441-51	9.7	273
183	Challenges of guarantee-time bias. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2963-9	2.2	271
182	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 122-137	59.2	270

181	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5569-75	2.2	262
180	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1346-1366	2.2	249
179	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3097-3104	2.2	215
178	Prediction of erectile function following treatment for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 1205-14	27.4	213
177	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 371-382	21.7	200
176	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1385-1393	21.7	195
175	Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 2096-104	15.1	192
174	Melatonin treatment for age-related insomnia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 4727-30	5.6	188
173	Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 207-12	9.7	183
172	Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4706-11	12.9	181
171	A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. <i>Fertility and Sterility</i> , <b>2010</b> , 94, 888-99	4.8	170
170	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 566-71	2.8	160
169	Precardiopulmonary bypass right ventricular function is associated with poor outcome after coronary artery bypass grafting in patients with severe left ventricular systolic dysfunction. <i>Anesthesia and Analgesia</i> , <b>2002</b> , 95, 1507-18, table of contents	3.9	153
168	Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 128-32	7	137
167	Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 23-8	21.7	131
166	Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1571-81	9.7	129
165	Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4951-7	2.2	119
164	Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1117-24	2.2	115

163	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 561-8	12.9	114
162	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2221-31	2.2	112
161	Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2966-73	2.2	107
160	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 848-58	21.7	106
159	Evaluation of the 8q24 prostate cancer risk locus and MYC expression. <i>Cancer Research</i> , <b>2009</b> , 69, 5568-74	10.1	102
158	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1485-1505	2.2	102
157	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2772-9	2.2	91
156	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1085-1093	13.4	88
155	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , <b>2009</b> , 115, 981-7	6.4	87
154	Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 842-7	2.2	86
153	Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1404-10	2.2	84
152	Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3967-75	2.2	83
151	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 545-563	5	82
150	Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. <i>Human Genetics</i> , <b>2003</b> , 113, 286-92	6.3	81
149	Incorporation of urea and ammonia nitrogen into ileal and fecal microbial proteins and plasma free amino acids in normal men and ileostomates. <i>American Journal of Clinical Nutrition</i> , <b>1999</b> , 70, 1046-58	7	81
148	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1601-10	2.2	75
147	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , <b>2010</b> , 106, 772-8	5.6	73
146	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 158, 323-31	4.4	73

145	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1941-1948	2.2	73
144	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1179-1188	2.2	71
143	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001204	6	70
142	Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. <i>Vaccine Journal</i> , <b>2004</b> , 11, 819-24		69
141	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3113-3122	2.2	68
140	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , <b>2014</b> , 120, 1076-82	6.4	65
139	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. <i>Breast</i> , <b>2013</b> , 22, 1094-100	3.6	63
138	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 127-138	21.7	62
137	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1073-1079	2.2	62
136	Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7099-105	12.9	59
135	Likelihood models for clustered binary and continuous outcomes: application to developmental toxicology. <i>Biometrics</i> , <b>1999</b> , 55, 760-8	1.8	57
134	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3400-8	2.2	56
133	Lysine requirements of healthy adult Indian subjects, measured by an indicator amino acid balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2001</b> , 73, 900-7	7	55
132	Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. <i>Breast Cancer Research</i> , <b>2011</b> , 13, 209	8.3	53
131	Cysteine kinetics and oxidation at different intakes of methionine and cystine in young adults. <i>American Journal of Clinical Nutrition</i> , <b>2000</b> , 71, 491-9	7	53
130	SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/βcatenin activation in breast cancer. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 6478-87	5.4	50
129	Lysine requirements of chronically undernourished adult Indian men, measured by a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 101-8	7	48
128	Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. <i>Journal of Virology</i> , <b>2001</b> , 75, 11234-8	6.6	48

127	Lysine requirements of healthy adult Indian subjects receiving long-term feeding, measured with a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2002</b> , 76, 404-12	7	45
126	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1293-1303	2.2	45
125	Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. <i>Journal of Urology</i> , <b>2014</b> , 191, 638-45	2.5	43
124	Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R143	8.3	43
123	Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. <i>Journal of the American College of Surgeons</i> , <b>2009</b> , 208, 202-9	4.4	43
122	Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1231-1241	10.3	43
121	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 6686-91	11.5	42
120	Relationship between serum adiponectin and prostate cancer grade. <i>Prostate</i> , <b>2008</b> , 68, 1592-8	4.2	41
119	Daily methionine requirements of healthy Indian men, measured by a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 1198-205	7	40
118	Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3282-7	12.9	39
117	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 105-114	2.2	38
116	Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. <i>Breast</i> , <b>2013</b> , 22, 130-137	3.6	38
115	Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 719-28	3.2	38
114	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 30	8.3	37
113	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. <i>BJU International</i> , <b>2008</b> , 101, 308-12	5.6	37
112	Intestinal parasites increase the dietary lysine requirement in chronically undernourished Indian men. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 78, 1145-51	7	33
111	Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. <i>Annals of Pharmacotherapy</i> , <b>1995</b> , 29, 459-64	2.9	33
110	Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. <i>BJU International</i> , <b>2011</b> , 107, 126-34	5.6	32

109	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. <i>Annals of Oncology</i> , <b>2010</b> , 21, 312-318	10.3	32
108	Physicians' experiences with BRCA1/2 testing in community settings. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5789-96	2.2	32
107	Threonine requirements of healthy Indian men, measured by a 24-h indicator amino acid oxidation and balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2002</b> , 76, 789-97	7	32
106	Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1332-4	9.7	31
105	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 121, 211-8	4.4	31
104	Daily requirement for and splanchnic uptake of leucine in healthy adult Indians. <i>American Journal of Clinical Nutrition</i> , <b>2001</b> , 74, 747-55	7	31
103	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 275-86	4.4	30
102	Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. <i>Journal of Neurosurgery: Spine</i> , <b>2010</b> , 13, 789-94	2.8	30
101	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 956-64	8.7	30
100	Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. <i>Cancer</i> , <b>2011</b> , 117, 517-25	6.4	29
99	Absence of relationship between steroid hormone levels and prostate cancer tumor grade. <i>Urology</i> , <b>2009</b> , 73, 356-61; discussion 361-2	1.6	28
98	Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. <i>American Journal of Epidemiology</i> , <b>2017</b> , 185, 75-85	3.8	27
97	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. <i>Urology</i> , <b>2004</b> , 63, 327-32	1.6	25
96	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 373-84	4.4	24
95	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1335-1343	13.4	24
94	Why do older women discontinue hormone replacement therapy?. <i>Journal of Women's Health and Gender-Based Medicine</i> , <b>2001</b> , 10, 343-50		24
93	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3350-3358	2.2	23
92	Predicting response to systemic treatments: learning from the past to plan for the future. <i>Breast</i> , <b>2005</b> , 14, 582-93	3.6	23

91	Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5408-13	2.2	22
90	Inotropes improve right heart function in patients undergoing aortic valve replacement for aortic stenosis. <i>Anesthesia and Analgesia</i> , <b>2004</b> , 98, 891-902	3.9	22
89	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. <i>BJU International</i> , <b>2005</b> , 96, 783-6	5.6	21
88	Two latent variable risk assessment approaches for mixed continuous and discrete outcomes from developmental toxicity data. <i>Journal of Agricultural, Biological, and Environmental Statistics</i> , <b>2001</b> , 6, 340-355	1.9	21
87	Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. <i>BJU International</i> , <b>2010</b> , 105, 1392-6	5.6	20
86	Branched-chain amino acid requirements in healthy adult human subjects. <i>Journal of Nutrition</i> , <b>2006</b> , 136, 256S-63S	4.1	20
85	Survey of breast-feeding practices and outcomes in the cystic fibrosis population. <i>Pediatric Pulmonology</i> , <b>2004</b> , 37, 362-7	3.5	20
84	Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 225-32	4.4	19
83	Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2483-91	3.1	19
82	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , <b>2016</b> , 2, 217-24	13.4	19
81	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz002	4.6	18
80	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 398-406	3.1	18
79	Leucine requirement and splanchnic uptake of leucine in chronically undernourished adult Indian subjects. <i>American Journal of Clinical Nutrition</i> , <b>2003</b> , 77, 861-7	7	18
78	Effect of cystine on the methionine requirement of healthy Indian men determined by using the 24-h indicator amino acid balance approach. <i>American Journal of Clinical Nutrition</i> , <b>2004</b> , 80, 1526-35	7	18
77	Threonine requirement of healthy adults, derived with a 24-h indicator amino acid balance technique. <i>American Journal of Clinical Nutrition</i> , <b>2002</b> , 75, 698-704	7	18
76	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 304-317	4	17
75	Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1868-76	7.9	17
74	Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. <i>Clinical Genitourinary Cancer</i> , <b>2006</b> , 5, 114-9	3.3	17



73	Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. <i>Urology</i> , <b>2007</b> , 70, 527-31	1.6	17
72	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1434-1441	8.7	17
71	Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. <i>Cancer</i> , <b>2012</b> , 118, 2651-8	6.4	16
70	The daily phenylalanine requirement of healthy Indian adults. <i>American Journal of Clinical Nutrition</i> , <b>2006</b> , 83, 1331-6	7	16
69	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 110	8.3	15
68	Exemestane with ovarian suppression in premenopausal breast cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1358-9	59.2	15
67	Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. <i>Immunotherapy</i> , <b>2018</b> , 10, 1241-1252	3.8	15
66	Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 862-866	2.2	14
65	Regression models and risk estimation for mixed discrete and continuous outcomes in developmental toxicology. <i>Risk Analysis</i> , <b>2000</b> , 20, 363-76	3.9	14
64	The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2563-2569	3.1	13
63	Secondary hormonal therapy in men with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2011</b> , 9, 95-103	3.3	13
62	Daily requirement for total sulfur amino acids of chronically undernourished Indian men. <i>American Journal of Clinical Nutrition</i> , <b>2004</b> , 80, 95-100	7	13
61	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 165-171	5.7	13
60	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , <b>2019</b> , 11, 283-295	3.8	13
59	Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. <i>PLoS ONE</i> , <b>2013</b> , 8, e64225	3.7	12
58	Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2007</b> , 13, 125-9	2.2	12
57	HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 129-138	7.5	11
56	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 543-55	4.4	11

55	Prevalence of germline variants in inflammatory breast cancer. <i>Cancer</i> , <b>2019</b> , 125, 2194-2202	6.4	10
54	Reply to L. Moscetti. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1628	2.2	10
53	The daily valine requirement of healthy adult Indians determined by the 24-h indicator amino acid balance approach. <i>American Journal of Clinical Nutrition</i> , <b>2005</b> , 82, 373-379	7	10
52	Are SOFT and TEXT results practice changing and how?. <i>Breast</i> , <b>2016</b> , 27, 122-5	3.6	10
51	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3259-3268	2.2	10
50	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 3	7.8	9
49	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e299-305	3.3	9
48	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. <i>Future Oncology</i> , <b>2013</b> , 9, 1477-87	3.6	9
47	Gender bias in the disposition of frozen embryos. <i>Fertility and Sterility</i> , <b>2001</b> , 76, 1181-4	4.8	9
46	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 131, 295-306	4.4	8
45	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2017</b> , 23, 63-67	2.2	8
44	The effect of a controlled 8-week metabolic ward based lysine supplementation on muscle function, insulin sensitivity and leucine kinetics in young men. <i>Clinical Nutrition</i> , <b>2012</b> , 31, 903-10	5.9	8
43	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naïve patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. <i>Quality of Life Research</i> , <b>2019</b> , 28, 109-119	3.7	8
42	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 181, 347-359	4.4	7
41	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	7
40	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4120-4129	2.2	7
39	Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial. <i>Breast</i> , <b>2020</b> , 53, 1-7	3.6	6
38	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz050	4.6	6

37	Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm. <i>Fertility and Sterility</i> , <b>2004</b> , 81, 714-5	4.8	6
36	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 557-568	4.4	5
35	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , <b>2020</b> , 12, 37-51	3.8	5
34	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 351-360	4.4	5
33	Intravenously infused 13C-leucine is retained in fasting healthy adult men. <i>Journal of Nutrition</i> , <b>2002</b> , 132, 1906-8	4.1	5
32	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 673-679	3.5	5
31	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. <i>Urology</i> , <b>2019</b> , 127, 53-60	1.6	4
30	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz049	4.6	4
29	Trial designs and results supporting treatment de-escalation and escalation. <i>Breast</i> , <b>2017</b> , 34 Suppl 1, S10-S12	3.6	4
28	Using clinical trial data to tailor adjuvant treatments for individual patients. <i>Breast</i> , <b>2007</b> , 16 Suppl 2, S98-104	3.6	4
27	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4
26	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6122-6131	12.9	4
25	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute® Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , <b>2020</b> , 26, 384-390	1.2	4
24	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 959-967	8.7	3
23	Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al. <i>Quality of Life Research</i> , <b>2018</b> , 27, 149-152	3.7	3
22	Dramatic and prolonged PSA response after retreatment with a PSA vaccine. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 362-4	3.3	3
21	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 185, 697-707	4.4	3
20	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 504-512	12.9	3

19	Predicting benefit of endocrine therapy for early breast cancer. <i>Breast</i> , <b>2015</b> , 24 Suppl 2, S129-31	3.6	2
18	A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , <b>2012</b> , 21, 621-8	3.6	2
17	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 <b>2021</b> , 9,		2
16	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz051	4.6	1
15	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.. <i>European Journal of Cancer</i> , <b>2022</b> , 164, 39-51	7.5	1
14	Risk stratification according to stage and pathology. <i>Breast</i> , <b>2019</b> , 48 Suppl 1, S23-S25	3.6	1
13	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. <i>Practical Radiation Oncology</i> , <b>2018</b> , 8, 445-451	2.8	1
12	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. <i>BMJ Open</i> , <b>2021</b> , 11, e045239	3	1
11	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.. <i>Oncologist</i> , <b>2022</b> , 27, 266-271	5.7	0
10	Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 449-455	2.7	0
9	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. <i>Cancer</i> , <b>2021</b> , 127, 700-708	6.4	0
8	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5472-5481	12.9	0
7	Reply to K.-D. Yu et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1516-1517	2.2	
6	Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?. <i>Breast</i> , <b>2022</b> ,	3.6	
5	Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9550-9550	2.2	
4	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 538-538	2.2	
3	Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4566-4566	2.2	
2	Statistical issues and challenges. <i>Cancer Treatment and Research</i> , <b>2009</b> , 151, 77-90	3.5	

1 Reply to F. Tomao et al. *Journal of Clinical Oncology*, **2016**, 34, 4189-4190

2.2